Middle East and Africa Infectious Disease Immunoassay Testing Market - Size, Share Outlook, Growth Analysis Report and Forecast Trends (2026-2035)

Read more about this report - Request a Free Sample

Middle East and Africa Infectious Disease Immunoassay Testing Market Overview

Infectious disease immunoassay testing is evolving with continuous advancements in diagnostic technologies that enable rapid, accurate, and reliable detection of infectious pathogens. These innovations are strengthening disease diagnosis, supporting timely clinical decision-making, and improving patient outcomes across healthcare settings. The market was valued at USD 710.00 Million in 2025, driven by the rising prevalence of infectious diseases, increasing healthcare expenditure, and expanding diagnostic infrastructure across the region. The growing awareness of early disease detection and increasing adoption of advanced immunoassay testing technologies are also expanding the market.

Middle East and Africa Infectious Disease Immunoassay Testing Market Growth Analysis and Key Influencers

Middle East and Africa Infectious Disease Immunoassay Testing Market Dynamics

This section analyzes factors influencing the market, including infectious disease prevalence, healthcare infrastructure expansion, laboratory modernization, regulatory frameworks, government initiatives, diagnostic technology adoption, healthcare investments, and improving access to immunoassay testing services.

Middle East and Africa Infectious Disease Immunoassay Testing Market Growth Drivers

Local Manufacturing Initiatives to Accelerate Regional Market Adoption Rates

Rising HIV and malaria screening needs and expanding domestic manufacturing are strengthening diagnostic access across African healthcare systems. For instance, in April 2026, Uganda launched locally manufactured rapid test kits for HIV and malaria, alongside a national HIV testing algorithm. This initiative may support market growth by reducing import dependence, improving supply continuity, shortening procurement timelines, and expanding availability of affordable immunoassay tools across public clinics, community programs, and regional laboratories throughout the country more widely.

Middle East and Africa Infectious Disease Immunoassay Testing Market Restraints

Product Quality Concerns Increase Compliance Pressure Across Regional Diagnostic Systems

High disease burdens and heavy reliance on rapid testing make product quality and reliable clinical performance essential across African health programs. For instance, in July 2026, Mozambique’s ANARME suspended malaria, HIV, and HIV-syphilis rapid diagnostic tests manufactured by Meril Diagnostics. These market restraints may increase supplier scrutiny, interrupt procurement, require replacement inventories, and raise validation costs for governments, laboratories, distributors, and healthcare providers operating across the country’s diagnostic system.

Middle East and Africa Infectious Disease Immunoassay Testing Market Opportunities

Technology Transfer Agreements Advancing Regional Market Expansion and Commercial Access

Limited regional production and recurring supply disruptions are encouraging technology transfer and investment in locally manufactured diagnostics. For instance, in May 2025, WHO and the Medicines Patent Pool announced a sublicense enabling Nigeria’s Codix Bio to develop and manufacture rapid tests using SD Biosensor technology. This agreement may create market opportunities by expanding African production capacity, reducing import reliance, supporting workforce development and improving access to affordable HIV and other infectious disease tests.

Middle East and Africa Infectious Disease Immunoassay Testing Market Trends

Domestic Production Partnerships to Support Regional Diagnostic Market Expansion

Government procurement priorities and regional supply resilience are shifting diagnostic strategies toward domestic manufacturing and technology partnerships. For instance, in July 2025, Tanzania announced plans to establish local production of rapid tests for HIV, syphilis, and hepatitis, with manufacturing targeted to begin in 2026. These market trends may encourage additional public-private agreements, strengthen local technical capabilities, reduce testing delays, and broaden access across hospitals, clinics, laboratories, and maternal healthcare programs.

Middle East and Africa Infectious Disease Immunoassay Testing Market Share

Laboratory Testing Likely to Dominate the Market Segment by Type of Testing

Growing laboratory modernization, expanding centralized diagnostic networks, and increasing demand for accurate infectious disease detection continue supporting advanced testing capabilities throughout the Middle East and Africa. Central laboratories remain essential for managing high testing volumes efficiently. Laboratory testing held about 69% market share in the historical period and is likely to dominate the market during the forecast period, supported by automation investments, healthcare expansion, and rising diagnostic requirements.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Read more about this report - Request a Free Sample

Middle East and Africa Infectious Disease Immunoassay Testing Market Analysis by Region

Saudi Arabia maintains a strong position within the Middle East and Africa infectious disease immunoassay testing market through expanding healthcare infrastructure, national disease surveillance initiatives, and investments in laboratory modernization. These efforts continue strengthening regional diagnostic capabilities. Saudi Arabia held about 31% market share in the historical period and is likely to dominate the market during the forecast period, supported by healthcare transformation programs and increasing diagnostic investments.

Leading Players in the Middle East and Africa Infectious Disease Immunoassay Testing Market

Middle East and Africa Infectious Disease Immunoassay Testing Market Segmentation

Key Questions Answered in the Middle East and Africa Infectious Disease Immunoassay Testing Market Report

• What was the Middle East and Africa infectious disease immunoassay testing market value in 2025?
• What is the Middle East and Africa infectious disease immunoassay testing market forecast outlook for 2026-2035?
• What major factors aid the demand for the Middle East and Africa infectious disease immunoassay testing market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major Middle East and Africa infectious disease immunoassay testing market trends?
• Which product and service segment is expected to dominate the market?
• Which type of testing segment is expected to hold the largest market share?
• Which sample type is expected to account for the highest market share?
• Which disease type is expected to account for the highest market share?
• Which technology is expected to account for the highest market share?
• Which application is expected to account for the highest market share?
• Which end user is expected to account for the highest market share?
• Who are the key players in the Middle East and Africa infectious disease immunoassay testing market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Research Methodology

This report is developed through a robust mixed-methods research design combining:

• Primary Research: Interviews with diagnostic manufacturers, laboratory managers, microbiologists, clinicians, regulatory specialists, and professionals involved in infectious disease immunoassay testing across Middle East and Africa.
• Secondary Research: Sources included company announcements, CE-marking updates, technical documents, MedTech Middle East and Africa publications, regulatory reports, scientific journals, and peer-reviewed studies on testing.
• Validation: All quantitative estimates are triangulated using top-down and bottom-up market modeling, validated through expert feedback loops.